The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance

被引：38
|
作者：
Goette, Matthias [1 ,2 ,3 ]
机构：
[1] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada
[3] McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 1A3, Canada
来源：
CURRENT OPINION IN VIROLOGY | 2012年 / 2卷 / 05期
基金：
加拿大健康研究院;
关键词：
HIV-1; REVERSE-TRANSCRIPTASE; CROSS-RESISTANCE; MUTATIONAL BIAS; NS5A INHIBITOR; VIRUS; PROTEASE; FIDELITY; REPLICATION; INFECTION; VARIANTS;
D O I：
10.1016/j.coviro.2012.08.004
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The selection of resistance to antiviral drugs depends on multiple parameters, including the genetic barrier that is often broadly defined as the number of mutations required to overcome drug selective pressure. In this review, it is intended to assess the roles of genetic barrier and viral fitness at various stages of the selection process. Several examples in the fields of HIV and HCV drug resistance show that the two parameters are distinct and independent. An analogy to the concept of kinetic versus thermodynamic control of chemical reactions supports a more narrow definition of the genetic barrier as the kinetic obstacle for the generation of genetic changes required to overcome selective pressure.
引用
收藏
页码：644 / 650
页数：7
相关论文
共 50 条
  • [1] Antiviral drug development and the impact of drug resistance
    Darby, G
    NEW CHALLENGES TO HEALTH: THE THREAT OF VIRUS INFECTION, 2001, 60 : 311 - 339
  • [2] Antiviral drugs and antiviral drug resistance
    Coen, Donald M.
    Whitley, Richard J.
    CURRENT OPINION IN VIROLOGY, 2011, 1 (06) : 545 - 547
  • [3] Antiviral drug resistance
    Richman, Douglas D.
    ANTIVIRAL RESEARCH, 2006, 71 (2-3) : 117 - 121
  • [4] Antiviral drug resistance
    Pillay, D
    Zambon, M
    BMJ-BRITISH MEDICAL JOURNAL, 1998, 317 (7159): : 660 - 662
  • [5] Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance
    Powdrill, Megan H.
    Tchesnokov, Egor P.
    Kozak, Robert A.
    Russell, Rodney S.
    Martin, Ross
    Svarovskaia, Evguenia S.
    Mo, Hongmei
    Kouyos, Roger D.
    Goette, Matthias
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (51) : 20509 - 20513
  • [6] Triple Combination Antiviral Drug (TCAD) Regimen Composed of Amantadine, Ribavirin, and Oseltamivir Imposes a High Genetic Barrier to the Development of Resistance Against Influenza A Viruses In Vitro
    Nguyen, Jack
    Hoopes, Justin
    Driebe, Elizabeth
    Sheff, Kelly
    Engelthaler, David
    Le, Minh
    Patick, Amy
    ANTIVIRAL RESEARCH, 2010, 86 (01) : A40 - A40
  • [7] Stochastic resetting antiviral therapies prevent drug resistance development
    Ramoso, A. M.
    Magalang, J. A.
    Sanchez-Taltavull, D.
    Esguerra, J. P.
    Roldan, E.
    EPL, 2020, 132 (05)
  • [8] The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance
    Schreiber, Andre
    Rodner, Franziska
    Oberberg, Nicole
    Anhlan, Darisuren
    Bletz, Stefan
    Mellmann, Alexander
    Planz, Oliver
    Ludwig, Stephan
    ANTIVIRAL RESEARCH, 2024, 225
  • [9] Estimating HIV evolutionary pathways and the genetic barrier to drug resistance
    Beerenwinkel, N
    Däumer, M
    Sing, T
    Rahnenführer, J
    Lengauer, T
    Selbig, J
    Hoffmann, D
    Kaiser, R
    JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (11): : 1953 - 1960
  • [10] Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response
    Deforche, Koen
    Cozzi-Lepri, Alessandro
    Theys, Kristof
    Clotet, Bonaventura
    Camacho, Ricardo J.
    Kjaer, Jesper
    Van Laethem, Kristel
    Phillips, Andrew
    Moreau, Yves
    Lundgren, Jens D.
    Vandamme, Anne-Mieke
    ANTIVIRAL THERAPY, 2008, 13 (03) : 399 - 407
12345